The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study ; volume:9 ; number:4 ; day:3 ; month:6 ; year:2022 ; pages:1109-1118 ; date:8.2022
Rheumatology and therapy ; 9, Heft 4 (3.6.2022), 1109-1118, 8.2022
- Urheber
-
Adrichem, Roxanne C. S. van
Voorneveld, Hanneke J. E.
Waverijn, Geeke J.
Kok, Marc R.
Bisoendial, Radjesh J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-022-00465-6
- URN
-
urn:nbn:de:101:1-2022100619582789789500
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Adrichem, Roxanne C. S. van
- Voorneveld, Hanneke J. E.
- Waverijn, Geeke J.
- Kok, Marc R.
- Bisoendial, Radjesh J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
AVT02: An Adalimumab Biosimilar
Correction to: AVT02: An Adalimumab Biosimilar
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Consistency of Product Quality for SB5, an Adalimumab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab